Compare Natera Inc. Common Stock (NTRA) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ProShares Ultra QQQ ETF — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while ProShares Ultra QQQ ETF trades at $90.53 (market cap $15.24B). The key difference: Natera Inc. Common Stock is far larger — about 3.7× ProShares Ultra QQQ ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| NTRA | QLD | |
|---|---|---|
Market Cap | $57.03B | $15.24B |
Volume | 1,131,157 | 4,894,545 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $100.77 |
52-Week Low | $179.42 | $57.16 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
QLD (ProShares Ultra QQQ ETF) trades at $96.42, down 0.68% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, positioning it as a less volatile alternative to triple-leveraged products during market downturns. Recent institutional buying by 180 Wealth Advisors LLC increased their position by 29.4% in Q2 2026, signaling confidence in the fund's strategy.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $95-$97 and resistance at $98-$99. While leveraged ETFs offer amplified returns, they carry elevated risk from daily rebalancing and market volatility. Investors should monitor Fed policy impacts and tech sector momentum for directional cues, with the current setup favoring tactical positions above key support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
